MC2050

MC2050 (25-100 μM; 0-72 h) does not reduce the viability of human SH-SY5Y neuroblastoma cells in adherent culture models, nor does it induce cell apoptosis^[1].
MC2050 (0-100 μM; 0-72 h) does not reduce the viability of EBV-latently infected human Raji Burkitt's lymphoma cells in suspension culture models^[1].
MC2050 (50 μM; 2-24 h) inhibits intracellular PARP-1 activity by 55%-60% in human SH-SY5Y neuroblastoma cells, and the inhibitory effect lasts up to 24 h^[1].
MC2050 (50 μM; 24-48 h) inhibits intracellular PARP-1 activity by up to 60% in EBV latently infected and EBV-induced lytic human Raji Burkitt's lymphoma cells^[1].
MC2050 (50 μM; 2 h) inhibits H₂O₂-induced overactivation of PARP-1 in human SH-SY5Y neuroblastoma cells^[1].
MC2050 (50 μM) inhibits H₂O₂-induced poly (ADP-ribosyl) ation modification of histone H1 in human SH-SY5Y neuroblastoma cells^[1].
MC2050 (1-100 μM; 30 min) concentration-dependently attenuates H₂O₂-induced cell death in human SH-SY5Y neuroblastoma cells^[1].
MC2050 (50 μM; 24-72 h) increases the protein level of EBNA1 by up to 2.5-fold in EBV lytic phase-induced human Raji Burkitt's lymphoma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.